Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. AMC
4. NVDA
5. NUAI
6. MSFT
7. ACN
8. FFAI
9. PAA
10. TLT

Go back to Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
(NASDAQ: RYTM) Delayed: 98.44 +0.73 (0.75%)
Previous Close $97.71    52 Week High $ 
Open $98.47    52 Week Low $ 
Day High $99.24    P/E N/A 
Day Low $97.54    EPS $ 
Volume 9,815